How many insider trades does FilingIQ track for ARCT?

FilingIQ tracks 74 Form 4 insider transactions for ARCT (Arcturus Therapeutics Holdings Inc.), covering filings from Aug 19, 2019 onwards. 1 of those were filed in the last 90 days.

Are ARCT insiders net buyers or net sellers?

Across the full Form 4 history for ARCT, 15 transactions (20%) were open-market purchases and 39 (53%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ARCT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ARCT in?

Arcturus Therapeutics Holdings Inc. (ARCT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $217.94M.

ARCT insider trading

NasdaqGM Healthcare

Arcturus Therapeutics Holdings Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

20% / 53%

Market cap

$217.94M

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Company website: arcturusrx.com

ARCT insider activity at a glance

FilingIQ has scored 74 insider transactions for ARCT since Aug 19, 2019. The most recent filing in our index is dated May 1, 2026.

Across the full history, 15 open-market purchases and 39 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ARCT insider trades is 60.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ARCT trades on FilingIQ Raw filings on SEC EDGAR

Latest ARCT Form 4 filings

SASSINE ANDY Chief Financial Officer

S Jun 12, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for ARCT?: FilingIQ tracks 74 Form 4 insider transactions for ARCT (Arcturus Therapeutics Holdings Inc.), covering filings from Aug 19, 2019 onwards. 1 of those were filed in the last 90 days.
Are ARCT insiders net buyers or net sellers?: Across the full Form 4 history for ARCT, 15 transactions (20%) were open-market purchases and 39 (53%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ARCT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ARCT in?: Arcturus Therapeutics Holdings Inc. (ARCT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $217.94M.

Methodology & sources

Every ARCT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.